News

SynCo Bio Partners (SynCo) has entered into a strategic partnership with Versartis to produce Versartis’ lead drug candidate – VRS-859. Under the agreement, SynCo will further develop the

Cellceutix has signed an agreement with Girindus America for the manufacture of Kevetrin active pharmaceutical ingredient. Terms of the agreement were not disclosed. Kevetrin is being developed to

AlphaRx has completed the lyophilization process for Zysolin, allowing the company to proceed to clinical batch material manufacturing for human trials. The company said that the process has

Ore Pharmaceuticals has reported a net loss of $2.5m, or $0.47 per share for the second quarter of 2009, a decrease when compared to a net loss of

The Valspar Corporation has reported its results for the third-quarter ended July 31, 2009. The company’s third-quarter sales totaled $794.6m, 17% lower than sales in the third quarter

Researchers from the University of Pittsburgh have reported two nanoscale devices (recently in two separate journals) harness the potential of carbon nanomaterials to enhance technologies for drug or

The Valspar Corporation has reported its results for the third-quarter ended July 31, 2009. The company’s third-quarter sales totaled $794.6m, 17% lower than sales in the third quarter

Santhera has reported that it has exercised its option to acquire Oy Juvantia Pharma, the owner of JP-1730/fipamezole. Reportedly, the company will issue up to 105,973 previously reserved

Vasogen and IntelliPharmaCeutics (IPC) have entered into a definitive agreement, subject to shareholder and regulatory approvals. As per the deal, Vasogen will combine with IPC under a plan